Talent advantage

Scinosen CDMO platform reserves high-tech talents with many years of actual production and quality control experience, and has formed a research and development team composed of academicians and experts at home and abroad. Its core technical team has more than 20 years of experience in large-scale adenovirus vector production and quality control, and participated in the formulation of China's "Technical Guidelines for Human Gene Therapy Research and Formulation Quality Control", which is still the world's most complete systematic technical guidelines for gene therapy research and formulation quality control, and is still a global guiding reference standard. Scinosen's production level of adenovirus vector gene drugs is leading in the world. The Scinosen CDMO/CMO platform will also build on its position in the industry and its product advantages to invest in a sub-assembly site and international services for the production of genetic drugs to maximize its value.

Under the leadership of Ms. Wei Xu, president of Harvard University and winner of the World's Outstanding Chinese award, Scinosen set up a research and development team represented by Dr. Weiwei Zhang, molecular biology, University of Alabama, USA; The team of scientists and clinical experts is represented by Academician Sun Yan of the Chinese Academy of Engineering, Academician Wu Zuze of the Chinese Academy of Sciences, Academician Zeng Yixin of the Chinese Academy of Sciences and Academician Wei Yuquan of the Chinese Academy of Sciences. It has joint research centers in Washington, the United States, and Weizmann College of Science in Israel, and has cooperated with Oxford, Harvard, Massachusetts Medical School, and Guangzhou Health of the Chinese Academy of Sciences in gene diagnosis and biological information interpretation. In recent years, Sanosen has made breakthroughs in gene medicine research and development:

1. mutant glucokinase adenovirus injection: gene therapy type 2 diabetes biological class A new drug, with national invention patent, PCT international patent, clinical application has been accepted;

2. NK: immunotherapy cancer biological class A new drug, has passed the national invention patent examination, PCT international patent application has been accepted;

3. CAR-NK: A new drug technology for immunotherapy of cancer biology, which has been authorized by the national invention patent.